Clinical Trial Update: Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the efficacy and safety of anlotinib combined with platinum and pemetrexed in T790M-negative metastatic lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Pemetrexed (pemetrexed)
• Platinum (Platinum-based chemotherapy)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Cancer Metastatic | Phase 1, Phase 2 | Status: UNKNOWN